Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.

LaBranche CC, Henderson R, Hsu A, Behrens S, Chen X, Zhou T, Wiehe K, Saunders KO, Alam SM, Bonsignori M, Borgnia MJ, Sattentau QJ, Eaton A, Greene K, Gao H, Liao HX, Williams WB, Peacock J, Tang H, Perez LG, Edwards RJ, Kepler TB, Korber BT, Kwong PD, Mascola JR, Acharya P, Haynes BF, Montefiori DC.

PLoS Pathog. 2019 Sep 17;15(9):e1008026. doi: 10.1371/journal.ppat.1008026. eCollection 2019 Sep.

2.

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2019 Mar 26;15(3):e1007646. doi: 10.1371/journal.ppat.1007646. eCollection 2019 Mar.

3.

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.

LaBranche CC, McGuire AT, Gray MD, Behrens S, Kwong PDK, Chen X, Zhou T, Sattentau QJ, Peacock J, Eaton A, Greene K, Gao H, Tang H, Perez LG, Chen X, Saunders KO, Kwong PD, Mascola JR, Haynes BF, Stamatatos L, Montefiori DC.

PLoS Pathog. 2018 Nov 5;14(11):e1007431. doi: 10.1371/journal.ppat.1007431. eCollection 2018 Nov. Erratum in: PLoS Pathog. 2019 Mar 26;15(3):e1007646.

4.

Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.

Schiffner T, Pallesen J, Russell RA, Dodd J, de Val N, LaBranche CC, Montefiori D, Tomaras GD, Shen X, Harris SL, Moghaddam AE, Kalyuzhniy O, Sanders RW, McCoy LE, Moore JP, Ward AB, Sattentau QJ.

PLoS Pathog. 2018 May 10;14(5):e1006986. doi: 10.1371/journal.ppat.1006986. eCollection 2018 May.

5.

Efferocytosis of Pathogen-Infected Cells.

Karaji N, Sattentau QJ.

Front Immunol. 2017 Dec 22;8:1863. doi: 10.3389/fimmu.2017.01863. eCollection 2017. Review.

6.

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.

Medina-Ramírez M, Sanders RW, Sattentau QJ.

Curr Opin HIV AIDS. 2017 May;12(3):241-249. doi: 10.1097/COH.0000000000000363. Review.

7.

Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material.

Russell RA, Chojnacki J, Jones DM, Johnson E, Do T, Eggeling C, Padilla-Parra S, Sattentau QJ.

Cell Rep. 2017 Feb 7;18(6):1473-1483. doi: 10.1016/j.celrep.2017.01.027.

8.

Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.

Persson J, Zhang Y, Olafsdottir TA, Thörn K, Cairns TM, Wegmann F, Sattentau QJ, Eisenberg RJ, Cohen GH, Harandi AM.

Front Immunol. 2016 Dec 26;7:640. doi: 10.3389/fimmu.2016.00640. eCollection 2016.

9.

Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns.

Gartlan KH, Krashias G, Wegmann F, Hillson WR, Scherer EM, Greenberg PD, Eisenbarth SC, Moghaddam AE, Sattentau QJ.

Vaccine. 2016 Apr 27;34(19):2188-96. doi: 10.1016/j.vaccine.2016.03.025. Epub 2016 Mar 19.

10.

Macrophages and HIV-1: An Unhealthy Constellation.

Sattentau QJ, Stevenson M.

Cell Host Microbe. 2016 Mar 9;19(3):304-10. doi: 10.1016/j.chom.2016.02.013. Review.

11.

Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.

Schiffner T, de Val N, Russell RA, de Taeye SW, de la Peña AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau QJ.

J Virol. 2015 Oct 28;90(2):813-28. doi: 10.1128/JVI.01942-15. Print 2016 Jan 15.

12.

The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.

Wegmann F, Moghaddam AE, Schiffner T, Gartlan KH, Powell TJ, Russell RA, Baart M, Carrow EW, Sattentau QJ.

Clin Vaccine Immunol. 2015 Sep;22(9):1004-12. doi: 10.1128/CVI.00736-14. Epub 2015 Jul 1.

13.

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, Cohen MS, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD.

Cell. 2015 Jun 4;161(6):1280-92. doi: 10.1016/j.cell.2015.05.007. Epub 2015 May 21.

14.

Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.

Sholukh AM, Watkins JD, Vyas HK, Gupta S, Lakhashe SK, Thorat S, Zhou M, Hemashettar G, Bachler BC, Forthal DN, Villinger F, Sattentau QJ, Weiss RA, Agatic G, Corti D, Lanzavecchia A, Heeney JL, Ruprecht RM.

Vaccine. 2015 Apr 21;33(17):2086-95. doi: 10.1016/j.vaccine.2015.02.020. Epub 2015 Mar 11.

15.

Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.

Bowles EJ, Schiffner T, Rosario M, Needham GA, Ramaswamy M, McGouran J, Kessler B, LaBranche C, McMichael AJ, Montefiori D, Sattentau QJ, Hanke T, Stewart-Jones GB.

PLoS One. 2014 Dec 9;9(12):e114709. doi: 10.1371/journal.pone.0114709. eCollection 2014.

16.

Macrophage infection via selective capture of HIV-1-infected CD4+ T cells.

Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ.

Cell Host Microbe. 2014 Dec 10;16(6):711-21. doi: 10.1016/j.chom.2014.10.010. Epub 2014 Nov 20.

17.

Dry roasting enhances peanut-induced allergic sensitization across mucosal and cutaneous routes in mice.

Moghaddam AE, Hillson WR, Noti M, Gartlan KH, Johnson S, Thomas B, Artis D, Sattentau QJ.

J Allergy Clin Immunol. 2014 Dec;134(6):1453-1456. doi: 10.1016/j.jaci.2014.07.032. Epub 2014 Sep 22. No abstract available.

18.

Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens.

Sheppard NC, Brinckmann SA, Gartlan KH, Puthia M, Svanborg C, Krashias G, Eisenbarth SC, Flavell RA, Sattentau QJ, Wegmann F.

Int Immunol. 2014 Oct;26(10):531-8. doi: 10.1093/intimm/dxu055. Epub 2014 May 20.

PMID:
24844701
19.

Immunogen design to focus the B-cell repertoire.

Sattentau QJ.

Curr Opin HIV AIDS. 2014 May;9(3):217-23. doi: 10.1097/COH.0000000000000054. Review.

PMID:
24675068
20.

High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.

Duncan CJ, Williams JP, Schiffner T, Gärtner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ.

J Virol. 2014 Feb;88(4):2025-34. doi: 10.1128/JVI.03245-13. Epub 2013 Dec 4.

21.

Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies.

Schiffner T, Sattentau QJ, Duncan CJ.

Vaccine. 2013 Dec 2;31(49):5789-97. doi: 10.1016/j.vaccine.2013.10.020. Epub 2013 Oct 17. Review.

PMID:
24140477
22.

Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.

Smalls-Mantey A, Connors M, Sattentau QJ.

PLoS One. 2013 Sep 10;8(9):e74858. doi: 10.1371/journal.pone.0074858. eCollection 2013.

23.

High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy.

Duncan CJ, Russell RA, Sattentau QJ.

AIDS. 2013 Sep 10;27(14):2201-6. doi: 10.1097/QAD.0b013e3283632ec4.

24.

Attachment factors.

Jolly CL, Sattentau QJ.

Adv Exp Med Biol. 2013;790:1-23. doi: 10.1007/978-1-4614-7651-1_1. Review.

PMID:
23884583
25.

Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis.

Noti M, Wojno ED, Kim BS, Siracusa MC, Giacomin PR, Nair MG, Benitez AJ, Ruymann KR, Muir AB, Hill DA, Chikwava KR, Moghaddam AE, Sattentau QJ, Alex A, Zhou C, Yearley JH, Menard-Katcher P, Kubo M, Obata-Ninomiya K, Karasuyama H, Comeau MR, Brown-Whitehorn T, de Waal Malefyt R, Sleiman PM, Hakonarson H, Cianferoni A, Falk GW, Wang ML, Spergel JM, Artis D.

Nat Med. 2013 Aug;19(8):1005-13. doi: 10.1038/nm.3281. Epub 2013 Jul 21.

26.

Development of prophylactic vaccines against HIV-1.

Schiffner T, Sattentau QJ, Dorrell L.

Retrovirology. 2013 Jul 17;10:72. doi: 10.1186/1742-4690-10-72. Review.

27.

Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Montefiori DC, Schief WR, Sattentau QJ.

J Virol. 2013 Sep;87(18):10163-72. doi: 10.1128/JVI.01161-13. Epub 2013 Jul 10.

28.

Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.

Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM; CAVD Project Group.

AIDS. 2013 Jun 1;27(9):F13-20. doi: 10.1097/QAD.0b013e328360eac6.

29.

The HIV-1-containing macrophage compartment: a perfect cellular niche?

Tan J, Sattentau QJ.

Trends Microbiol. 2013 Aug;21(8):405-12. doi: 10.1016/j.tim.2013.05.001. Epub 2013 Jun 2. Review.

PMID:
23735804
30.

Multiple proviral integration events after virological synapse-mediated HIV-1 spread.

Russell RA, Martin N, Mitar I, Jones E, Sattentau QJ.

Virology. 2013 Aug 15;443(1):143-9. doi: 10.1016/j.virol.2013.05.005. Epub 2013 May 28.

31.

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens.

Sattentau QJ.

Vaccines (Basel). 2013 Oct 28;1(4):497-512. doi: 10.3390/vaccines1040497. Review.

32.

Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.

Kong L, Sattentau QJ.

J AIDS Clin Res. 2012;S8:3. Epub 2012 Mar 22.

33.

Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.

Wegmann F, Gartlan KH, Harandi AM, Brinckmann SA, Coccia M, Hillson WR, Kok WL, Cole S, Ho LP, Lambe T, Puthia M, Svanborg C, Scherer EM, Krashias G, Williams A, Blattman JN, Greenberg PD, Flavell RA, Moghaddam AE, Sheppard NC, Sattentau QJ.

Nat Biotechnol. 2012 Sep;30(9):883-8.

34.

The direct passage of animal viruses between cells.

Sattentau QJ.

Curr Opin Virol. 2011 Nov;1(5):396-402. doi: 10.1016/j.coviro.2011.09.004. Epub 2011 Oct 6. Review.

PMID:
22440841
35.

Vaccinology: A sweet cleft in HIV's armour.

Sattentau QJ.

Nature. 2011 Dec 14;480(7377):324-5. doi: 10.1038/480324a. No abstract available.

PMID:
22170674
36.

Viral determinants of HIV-1 macrophage tropism.

Duncan CJ, Sattentau QJ.

Viruses. 2011 Nov;3(11):2255-79. doi: 10.3390/v3112255. Epub 2011 Nov 15. Review.

37.

The regulated secretory pathway in CD4(+) T cells contributes to human immunodeficiency virus type-1 cell-to-cell spread at the virological synapse.

Jolly C, Welsch S, Michor S, Sattentau QJ.

PLoS Pathog. 2011 Sep;7(9):e1002226. doi: 10.1371/journal.ppat.1002226. Epub 2011 Sep 1.

38.

Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based human immunoglobulin transloci.

Pruzina S, Williams GT, Kaneva G, Davies SL, Martín-López A, Brüggemann M, Vieira SM, Jeffs SA, Sattentau QJ, Neuberger MS.

Protein Eng Des Sel. 2011 Oct;24(10):791-9. doi: 10.1093/protein/gzr038. Epub 2011 Aug 2.

PMID:
21810921
39.

Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidative stress.

Moghaddam AE, Gartlan KH, Kong L, Sattentau QJ.

J Immunol. 2011 Aug 15;187(4):1626-33. doi: 10.4049/jimmunol.1003906. Epub 2011 Jul 8.

40.

Architecture and regulation of the HIV-1 assembly and holding compartment in macrophages.

Welsch S, Groot F, Kräusslich HG, Keppler OT, Sattentau QJ.

J Virol. 2011 Aug;85(15):7922-7. doi: 10.1128/JVI.00834-11. Epub 2011 May 25.

41.

A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.

Wegmann F, Krashias G, Lühn K, Laamanen K, Vieira S, Jeffs SA, Shattock RJ, Sattentau QJ.

PLoS One. 2011 Jan 6;6(1):e15861. doi: 10.1371/journal.pone.0015861.

42.

New templates for HIV-1 antibody-based vaccine design.

Sattentau QJ, McMichael AJ.

F1000 Biol Rep. 2010 Aug 9;2:60. doi: 10.3410/B2-60.

43.

Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.

Kong L, Sheppard NC, Stewart-Jones GBE, Robson CL, Chen H, Xu X, Krashias G, Bonomelli C, Scanlan CN, Kwong PD, Jeffs SA, Jones IM, Sattentau QJ.

J Mol Biol. 2010 Oct 15;403(1):131-147. doi: 10.1016/j.jmb.2010.08.033. Epub 2010 Aug 25.

44.

Cell-to-Cell Spread of Retroviruses.

Sattentau QJ.

Viruses. 2010 Jun;2(6):1306-21. doi: 10.3390/v2061306. Epub 2010 Jun 10.

45.

Retroviruses and the third synapse.

Sattentau QJ.

Viruses. 2010 Apr;2(4):1008-10. doi: 10.3390/v2041008. Epub 2010 Apr 15. No abstract available.

46.

SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse.

González N, Bermejo M, Calonge E, Jolly C, Arenzana-Seisdedos F, Pablos JL, Sattentau QJ, Alcamí J.

J Virol. 2010 May;84(9):4341-51. doi: 10.1128/JVI.02449-09. Epub 2010 Feb 24.

47.

Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.

Krashias G, Simon AK, Wegmann F, Kok WL, Ho LP, Stevens D, Skehel J, Heeney JL, Moghaddam AE, Sattentau QJ.

Vaccine. 2010 Mar 16;28(13):2482-9. doi: 10.1016/j.vaccine.2010.01.046. Epub 2010 Feb 2.

PMID:
20132920
48.

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A.

PLoS One. 2010 Jan 20;5(1):e8805. doi: 10.1371/journal.pone.0008805.

49.

Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition.

Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ.

J Virol. 2010 Apr;84(7):3516-27. doi: 10.1128/JVI.02651-09. Epub 2010 Jan 20.

50.

Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread.

Romer D, Brighty DW, Robson CL, Sattentau QJ.

Antimicrob Agents Chemother. 2009 Feb;53(2):678-87. doi: 10.1128/AAC.01550-07. Epub 2008 Dec 1.

Supplemental Content

Loading ...
Support Center